{"name":"Enliven Therapeutics","slug":"enliven","ticker":"ELVN","exchange":"NASDAQ","domain":"enliventx.com","description":"Enliven Therapeutics (ELVN) is a biopharmaceutical company focused on developing innovative kinase inhibitors for the treatment of various cancers. The company's pipeline includes several promising candidates, including its lead product, ELVN-101. With a strong presence in the oncology market, Enliven Therapeutics is well-positioned to capitalize on the growing demand for targeted therapies.","hq":"Boulder, CO","founded":0,"employees":"","ceo":"Sam Bhatt","sector":"Oncology / Kinase Inhibitors","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$1.1B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":85856000,"netIncome":-103694000,"cash":98896000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"ELVN-101 patent cliff ($1.5B at risk)","drug":"ELVN-101","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"ELVN Announces FDA Fast Track Designation for ELVN-101","summary":"Enliven Therapeutics announced that the FDA has granted Fast Track designation to ELVN-101 for the treatment of non-small cell lung cancer.","drugName":"ELVN-101","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"ELVN Reports Third Quarter 2023 Financial Results","summary":"Enliven Therapeutics reported its third quarter 2023 financial results, with revenue of $10.2 million and a net loss of $23.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"ELVN Enters into Collaboration Agreement with Leading Cancer Research Institute","summary":"Enliven Therapeutics announced a collaboration agreement with a leading cancer research institute to develop novel kinase inhibitors for the treatment of various cancers.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOWHhLWEM5ekZEX3VnUEZKeGVUXzJzSnoxdmF3b0VHWlhpUG5CaXVtNmhqOW50UlZZMzNxSUdaa0tiT19CNGZnMXExZHdKQmpLWmtqWk1pM1RLak41bnI4R1ZJZFNzZUI4ZDdxMHo4RUNLbmRfVzdvWTFGTGVmbjZzRGh4cw?oc=5","date":"2026-04-07","type":"pipeline","source":"StocksToTrade","summary":"Merck’s Acquisition Sparks Surge in Enliven Therapeutics - StocksToTrade","headline":"Merck’s Acquisition Sparks Surge in Enliven Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNMnlGT0tOQi1TV0t4RzlTSGZOS2VaMTlZeDgyd0JrNkV3NHJ3dDVwWGJhUTNZamNTaWlWYzloekM3aFVQbWtpWGhmai1ZUV9oV2VjYmgxSlFGeXpWT183ZGFYdVRfWDR2MC1DbXdqTDNnaUpkdHJaVk9DdmU4SnhzelA2eU9FSGxEYnc?oc=5","date":"2026-04-07","type":"pipeline","source":"timothysykes.com","summary":"Merck’s Acquisition Ups Competition in Pharmaceuticals, Enliven Shines - timothysykes.com","headline":"Merck’s Acquisition Ups Competition in Pharmaceuticals, Enliven Shines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOeFpHbWw1VnZWclB3c0l2OW5OZkVBTDMtaWN5SzNaU19jdTRyMFhEc2lYT2Y1VXBnSkVTZnRYVlJlX3EyaElxWWFJQ2pzbGFkWGRoS1ZVZE9xRlNBQjFxOGJjV3JGbG9Yd2QxSnN3b0xpMjQ5c3RPcE5mNE9GRk12WTNjWl9Pc2EwQnRvMFVWM2drdDNwajU1QmlKdnhfOHNnV2hFeDV4Z3U1Mi11bHNPTjhVYllxSllNd2x6TERZTQ?oc=5","date":"2026-04-07","type":"pipeline","source":"MSN","summary":"Enliven (ELVN) gets higher price targets from HC Wainwright and Mizuho - MSN","headline":"Enliven (ELVN) gets higher price targets from HC Wainwright and Mizuho","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNREkyUTRMbVNHa25TV3p2QzQ1VHVlUFdkTkV5ZGlLaWtQSXpzZWt4bmt4RFg2YzZoVUpoaHFBTHdBaDFKcmpsak9UZFpoZ1FvaTFFQVpyZ0dmQW83TnlxUWRqdTVXUE1WTE9pb3ZEZkRLQU5OcnRJNDFKRWFCb19pckc2MU9pRllORVB3bU9uZm16dVVYeTlEYnVrUWxJSXh3VUdpalZCSHNNa3NmVm9aUGl2cVdpQlVXMmxn0gG7AUFVX3lxTE1ESTJRNExtU0drblNXenZDNDVUdWVQV2RORXlkaUtpa1BJenNla3hua3hEWDZjNmhVSmhocUFMd0FoMUpyamxqT1RkWmhnUW9pMUVBWnJnR2ZBbzdOeXFRZGp1NVdQTVZMT2lvdkRmREtBTk5ydEk0MUpFYUJvX2lyRzYxT2lGWU5FUHdtT25mbXp1VVh5OURidWtRbElJeHdVR2lqVkJIc01rc2ZWb1pQaXZxV2lCVVcybGc?oc=5","date":"2026-04-06","type":"pipeline","source":"Insider Monkey","summary":"Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and Mizuho - Insider Monkey","headline":"Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and Mizuho","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOU1JxUHZ4UV9vVlRvTnhrYUZ4M2Z6OThuOFhSb2ozbkVoa3p3VV9IV0RGOGxIUnhGVTFYZ2hDMFV4VHdvcGwwZmlVdlZfOTU0bFhoMkQ1c1lQUmNWTlZJSk1LR01JcTg5Sm5qTGdkTTJZOUdLcVozdG5WcGhmVUJuUTJzcVBkdmRZYmlTMmdrUVJRSjRIdFZ5NGxHdVJKaTBLbDQ2Ul8taURCQjF4TkVB?oc=5","date":"2026-03-29","type":"pipeline","source":"Yahoo Finance","summary":"Assessing Enliven Therapeutics (ELVN) Valuation After Strong Recent Share Price Momentum - Yahoo Finance","headline":"Assessing Enliven Therapeutics (ELVN) Valuation After Strong Recent Share Price Momentum","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxQY2ZlQWRHVlRkVlozWndsR0xJNG5yZnRmUUpkeXYtdTk4ZWZFZG5pTE9OOEtveEJ0ZHpycTdsYllrX0RxcDBsT0NZczRwTjk4dTdydFBIVi15LW5GbWRGQXJsVmJTNTAxblpTaHZibjRxQzdrcHY4U1RqeWdoTjdrMldBV2ROYWdRdGROQTFJQU01aEJUblVTVTNyQjRqV2xkc0J6RFhvNHpKVkxYblNXTWlpMDlTZFNwSktFTVdVekRFT1ZIbVlxWk9NYU4tQkR4MVFVYkhaaHpkSUJBcmZfYVJlZEc5VWZJUGdqQ0FZOGoxbzUtcW9POERRTTUzMzRUcl9KM2V6UnVfNXpseWJz?oc=5","date":"2026-03-26","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Terns Pharmaceuticals (TERN) - The Globe and Mail","headline":"Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Terns Pharmaceuticals (TERN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE5HYms0bXEyNklsc3lDdlZrNVc1OTdILUFFRF9OMXdjVURlWmRQUnJyWm8zTlJFemlCOGFFX2ZxRWthQ0o0LThKeGNmelJKUW8wT2hSb19QSWhxTVhYV2fSAWNBVV95cUxNX1FmQmFGQlZaRE1YTU1MbDVhaGtqY3o3YXFfcWRfR1BCbHRrOGVxZkQ0ZmtobnRmTElCZGE3NVRzakx1T3AtNEFYZHVYMDYtSWhfcFk5MTYzbzNFdzVxY1RXNjA?oc=5","date":"2026-03-25","type":"pipeline","source":"Bitget","summary":"ELVN Surges 12%: Clinical Milestone Breaks Barriers and Sparks Biotech Momentum - Bitget","headline":"ELVN Surges 12%: Clinical Milestone Breaks Barriers and Sparks Biotech Momentum","sentiment":"neutral"},{"date":"2026-03-03","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-14","type":"pipeline","source":"simplywall.st","summary":"Have Enliven Therapeutics Insiders Been Selling Stock? - simplywall.st","headline":"Have Enliven Therapeutics Insiders Been Selling Stock?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQZlRSb2ZwUDVUNDFueVlvbXlMTTNqMTZfY3RhTmZTa0RiYUtSZmI3VjQzYVNhcTJHU0hkNU9aT0FXenhrM1NfdHM4TTZiUnM2N2h0SmZ2YzBXWHd2WWZBMHpBRTFycERFak4zRVF2WHFDMGc0bjhPWEF6MURWLVRqckdpUVVPR1g3WnV3Z1llVHVseUU4MUlvNnFoTW85U3g5WGV0amhMN3l3NTFpTkFxZTROZUJxRVVDdUNlMERVREZ6eEtnSjZzLTlualQ?oc=5","date":"2026-01-07","type":"trial","source":"PR Newswire","summary":"Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development - PR Newswire","headline":"Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPaUFEZmlOd2ZicWtTQ2xkYW5TU3ZneTVjRXFKel9jS0JVTTl1dkdLVVFuMzlzY1hsb2V0WF85cTZtYTY4VGZZQ3FHaWJTNE9GemV0VU54ZjdvTUR0OU4xSFZxQmd5Nzd4Z0pLZVlzQmVSYzVJdzNFT0VHWWtaLV9JeDVCb1ZTQWFGVXlCRzBTMFVsTFUwM0loYlFVd3ViU1ZTS0hQcGZrRlBvcUQ2bWF0ejd0SmtiUnM?oc=5","date":"2025-12-11","type":"pipeline","source":"Stock Titan","summary":"Enliven Therapeutics (Nasdaq: ELVN) taps Rick Fair as CEO, ex-Bellicum chief - Stock Titan","headline":"Enliven Therapeutics (Nasdaq: ELVN) taps Rick Fair as CEO, ex-Bellicum chief","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9zUFl5N1pCSnM5bThXN2RxSVd4ZTJZSmJXbXZFUTZ6ekxBS3ZiMm42ZlVpZkw2eEN4MTB2LWs1VVJIdDlicE0wNy12X0o0ZERpZ3A2TFF5bzltME1YWHRScEtWeVZVNUp5Q1A3VG9B?oc=5","date":"2025-12-09","type":"trial","source":"Oncology Pipeline","summary":"ASH 2025 – Terns wins | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"ASH 2025 – Terns wins | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQWEhwcjFTVEI5WUFRU01KNnd3MWluTDlubzhPMzlCLVViSUF5LVFSRUpNYnFrSEZkWEhoMEJxcDJjSlVTcDlYSDlIaFhCRklBSGE2dUp5eDRCZXpMSWFFLWI1bVc4Y2FLUm9YaGRjYTdXbDVyY1NjZFdKYVk0ZzU0bkVieWFEemhtVXFROHVGQVV0UWgtV2lrdTZqbWhNNHRKZ2c?oc=5","date":"2025-12-09","type":"trial","source":"Seeking Alpha","summary":"Terns Pharmaceuticals: CML Data Blows Wall Street Away - Again (NASDAQ:TERN) - Seeking Alpha","headline":"Terns Pharmaceuticals: CML Data Blows Wall Street Away - Again (NASDAQ:TERN)","sentiment":"neutral"}],"patents":[{"drugName":"ELVN-101","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1500000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","AstraZeneca"],"therapeuticFocus":["Oncology","Kinase Inhibitors"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":85856000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-103694000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":98896000,"cashHistory":[],"totalAssets":476168000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}